Henry Schein Inc. ($HSIC) Stock Forecast: Up 3.9% Today

What is Henry Schein Inc.?

HSIC (Henry Schein, Inc.) is a major healthcare solutions distributor that plays a significant role in the distribution of healthcare products and services.

Why is Henry Schein Inc. going up?

HSIC stock is up 3.9% on Jan 15, 2026 15:43

• The appointment of Frederick M. Lowery, a seasoned executive with a background in the healthcare industry, as the new CEO of Henry Schein has brought a fresh perspective to the company's leadership.
• The strategic shift in leadership, with Stanley M. Bergman transitioning to Chairman, signifies a governance reframe that aims to drive operational efficiencies and growth in specialty products and technology.
• Investors seem optimistic about the potential impact of the new CEO's expertise in distribution and product businesses on Henry Schein's strategic goals, leading to a bullish market movement for the stock.

HSIC Price Chart

HSIC Technical Analysis

HSIC News

Prudential plc names ex-HSBC top man Douglas Flint to succeed Shriti Vadera as Chair

Prudential plc has announced that Sir Douglas Flint, former Group Chair of HSBC, will become its new Chair, succeeding Baroness Shriti Vadera. He will join the board in March and officially take over after the company’s annual general meeting on May 28, 2026, marking the end of Vadera's six-year tenure. Prudential offers life and health insurance and asset management across Greater China, ASEAN, India, and Africa.

https://www.asiainsurancereview.com/News/ViewNewsLetterArticle/id/94139/Type/eDaily/Prudential-plc-names-ex-HSBC-top-man-Douglas-Flint-to-succeed-Shriti-Vadera-as-Chair

Medicare sets $300 price for IBS test as Biomerica expands AI diet tool

Biomerica announced its Q2 fiscal year 2026 results, showing a decline in revenue but an improved six-month net loss and reduced operating expenses, reflecting a strategic shift towards higher-margin diagnostic products. The Centers for Medicare & Medicaid Services (CMS) has set a $300 national Medicare payment rate for Biomerica's inFoods IBS test, effective January 1, 2026, which is expected to expand patient access. Additionally, Biomerica launched an AI-backed digital companion tool, the inFoods IBS Trigger Food Navigator, to enhance personalized IBS therapy and patient compliance.

https://www.stocktitan.net/news/BMRA/biomerica-reports-second-quarter-fiscal-2026-financial-t3826d12ddxm.html

Henry Schein Taps Former Thermo Fisher Exec as New CEO

Henry Schein, a major healthcare solutions distributor, has appointed Frederick M. Lowery as its new CEO, effective March 2. Lowery, previously an Executive Vice President at Thermo Fisher Scientific, will succeed Stanley M. Bergman, who is stepping down after 35 years but will remain Chairman of the Board. Lowery's extensive experience in healthcare distribution and product businesses aligns with Henry Schein's strategic goals for its next growth phase.

https://www.mdm.com/news/breaking-news-in-wholesale-distribution/henry-schein-taps-former-thermo-fisher-exec-as-new-ceo/

Henry Schein nomeia Frederick M. Lowery como Chief Executive Officer

Henry Schein, Inc. (Nasdaq: HSIC) announced the appointment of Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026. Lowery brings over two decades of experience in the healthcare industry, having most recently served as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher Scientific. He succeeds Stanley M. Bergman, who will remain Chairman of the Board.

https://www.jornaldentistry.pt/news/noticias/henry-schein-nomeia-frederick-m-lowery-como-chief-executive-officer-

Will Henry Schein’s (HSIC) New External CEO and Governance Shift Reframe Its Leadership Narrative?

Henry Schein (HSIC) has appointed Frederick M. Lowery as its new CEO, effective March 2, 2026, with current CEO Stanley M. Bergman transitioning to Chairman. This leadership change, alongside an amendment to company by-laws allowing a CEO to serve without also being President or Chairman, signals a more flexible governance approach. The article suggests this external hire, with expertise in distribution and product, could influence Henry Schein's strategy and ongoing efforts to achieve operational efficiencies and growth in specialty products and technology.

https://simplywall.st/stocks/us/healthcare/nasdaq-hsic/henry-schein/news/will-henry-scheins-hsic-new-external-ceo-and-governance-shif

Trending Today

Axie Infinity ($AXS) Crypto Forecast: Up 11.0% Today

Bittensor ($TAO) Crypto Forecast: Up 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 16.9% Today

Halliburton Company ($HAL) Stock Forecast: Up 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 6.8% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 6.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 18.5% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 20.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.9% Today

Henry Schein Inc. Price History

04.10.2025 - HSIC Stock was up 13.7%

• HSIC stock experienced a strong bullish movement today following the release of their Q3 earnings report.
• The earnings and revenue beats by +8.66% and +2.02% respectively have exceeded market expectations, indicating strong performance by the company.
• Investors are likely optimistic about the future prospects of HSIC, as the positive results suggest continued growth and profitability in the healthcare industry.
• The beat in earnings and revenues could attract more investors to the stock, driving up demand and pushing the stock price higher.

04.10.2025 - HSIC Stock was up 10.4%

• HSIC stock saw a surge following the announcement of better-than-expected Q3 earnings and revenue, exceeding analyst estimates by a notable margin.
• Boosting investor confidence, the company's decision to raise its 2025 outlook due to solid business momentum played a significant role in the stock's upward movement.
• The positive surprises in earnings and revenue point towards robust performance and growth potential for Henry Schein, eliciting increased optimism among investors and driving the stock price higher.

05.04.2025 - HSIC Stock was up 5.0%

• Despite missing revenue expectations, Henry Schein's Q1 earnings beat estimates, showing resilience in its business fundamentals.
• The rise in Global Specialty Products sales, driven by implants, biomaterials, and acquisitions, indicates a strong performance in key segments.
• The CEO's confidence in the business fundamentals suggests a positive outlook for the stock, leading to a strong bullish movement today.

11.11.2024 - HSIC Stock was up 5.5%

• HSIC stock experienced a notable increase today.
• Investor confidence appears to have improved following the latest earnings update from Henry Schein.
• Optimism among investors regarding the future performance of HSIC contributed to the bullish market trend.
• Positive earnings forecasts and growth potential are likely factors fueling the upward movement of HSIC stock.

25.01.2025 - HSIC Stock was down 4.5%

• The stock of Henry Schein (HSIC) displayed strong bearish movement today.
• Even though Q4 earnings estimates were met, the stock faced a notable decline, suggesting that investors expected stronger performance.
• Despite slightly surpassing revenue expectations, concerns about future growth prospects likely contributed to the significant market downturn.
• Investors responded negatively to the Q4 outlook and key metrics, triggering a sell-off in the stock.

05.10.2024 - HSIC Stock was down 3.0%

• Despite surpassing earnings and revenue expectations for Q3, Henry Schein (HSIC) witnessed significant bearish movement in its stock.
• The market's negative response might be attributed to the company falling short of Wall Street's forecasted key metrics, prompting a sell-off.
• Investors may have anticipated stronger performance from HSIC, with the deviation from expectations potentially sparking the bearish trend.
• Factors such as profit-taking or broader market conditions detached from the company's operations could also have influenced the decline in HSIC's stock price.

19.11.2024 - HSIC Stock was down 5.1%

• Despite the favorable outlook for HSIC's dental business, the stock showed a decline in value today.
• This downward movement could be attributed to investors taking profits following a period of consistent stock price growth.
• There are potential concerns among some investors regarding general market conditions or specific challenges facing the company, which might affect HSIC's future performance.
• The current bearish trend in HSIC's stock price could be a result of investors reassessing their positions in light of market uncertainties, despite the optimism surrounding the company's dental business.

15.00.2026 - HSIC Stock was up 3.9%

• The appointment of Frederick M. Lowery, a seasoned executive with a background in the healthcare industry, as the new CEO of Henry Schein has brought a fresh perspective to the company's leadership.
• The strategic shift in leadership, with Stanley M. Bergman transitioning to Chairman, signifies a governance reframe that aims to drive operational efficiencies and growth in specialty products and technology.
• Investors seem optimistic about the potential impact of the new CEO's expertise in distribution and product businesses on Henry Schein's strategic goals, leading to a bullish market movement for the stock.

05.07.2025 - HSIC Stock was down 5.3%

• The decline in HSIC stock today might be a result of investors taking profits in anticipation of the upcoming Q2 earnings announcement.
• Despite the likelihood of surpassing earnings expectations, some market participants seem to have opted to unload their positions, contributing to the stock's downward trajectory.
• This pattern could signal a scenario where investors who purchased shares in anticipation of positive earnings are now divesting to secure gains prior to the official release.

05.07.2025 - HSIC Stock was down 9.2%

• HSIC stock experienced downward movement after falling short of Q2 earnings estimates by 6.8%.
• The company surpassed revenue expectations with a 3.2% growth and exhibited strength across key segments, but the market responded negatively to the earnings miss.
• Concerns about future earnings potential and growth prospects may be driving the downward pressure on HSIC stock for investors.
• The mixed results of earnings and revenues could be causing uncertainty among investors, leading to a sell-off of HSIC shares in the current trading session.

10.06.2025 - HSIC Stock was up 2.6%

• Investor confidence in HSIC is high, attributed to the successful performance of Henry Schein One.
• Potential obstacles for the company include macroeconomic pressures and strong competition.
• Nevertheless, the optimistic outlook on HSIC appears to have overshadowed these challenges, resulting in a bullish trend in the stock today.

06.04.2025 - HSIC Stock was up 5.2%

• Despite mixed results for the first quarter, Henry Schein's stock showed bullish movement, reflecting investor confidence.
• The better-than-expected adjusted EPS likely bolstered the bullish trend, demonstrating effective earnings management.
• The shortfall in sales expectations may have been outweighed by the positive earnings surprise, fostering positive market sentiment.
• Overall, the CEO's confidence in the business fundamentals following the mixed earnings report seemed to reassure investors and influence the stock's bullish movement.